TherapeuticsMD (TXMD) Total Liabilities (2010 - 2026)

TherapeuticsMD (TXMD) has reported Total Liabilities for 17 consecutive years, with $10.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Liabilities fell 7.27% year-over-year to $10.4 million; the trailing twelve-month figure through Jun 2026 stood at $10.4 million (down 7.27% YoY), and the FY2025 full-year result was $10.8 million, down 5.87% from the prior year.
• Total Liabilities retreated to $10.4 million in Q2 2026 per TXMD's latest filing, from $10.6 million in the prior quarter.
• Across five years, Total Liabilities topped out at $274.0 million in Q1 2022 and bottomed at $10.4 million in Q2 2026.
• Historically, Total Liabilities has averaged $49.2 million across 5 years, with a median of $12.9 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Total Liabilities climbed 10.12% in 2022, then sank 89.93% in 2023.
• Over 5 years, Total Liabilities stood at $55.3 million in 2022, then sank by 74.65% to $14.0 million in 2023, then slipped by 18.33% to $11.5 million in 2024, then decreased by 5.87% to $10.8 million in 2025, then retreated by 3.55% to $10.4 million in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered $10.4 million, $10.6 million, and $10.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.